Clinical Research Directory

Inclusion Criteria: * Patient has provided written informed consent using the PBM PICF * Age ≥ 18 years of age at Screening * Histological diagnosis of HNC of the oral cavity with no evidence of macroscopic or microscopic residual disease post-surgery (R0 or R1 resection) with histopathological confirmation and no gross residual lymphadenopathy in the planned PBM treatment area * Planned treatment with RT or chemoradiotherapy to a dose of ≥ 50 Gy Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix 1) * Intact oral mucosa (no visible ulceration, dehiscence, or active infection) Exclusion Criteria: * Gross macroscopic and/or microscopic residual disease post-surgery (R2 resection) or gross residual lymphadenopathy in the planned PBM treatment area * Prior RT to the head and neck including the oral or oropharyngeal mucosa * Prior cytotoxic chemotherapy in the last 3 months * Diagnosis of photosensitive disorder (cutaneous porphyria, xeroderma pigmentosum, etc) * Concurrent administration of cetuximab * Known to be pregnant or planning to become pregnant within the trial period * Diagnosis of epilepsy